VSAR - Versartis, Inc.

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Do You Know Who Else Invests In Versartis Inc (NASDAQ:VSAR)?
    Simply Wall St.6 months ago

    Do You Know Who Else Invests In Versartis Inc (NASDAQ:VSAR)?

    Every investor in Versartis Inc (NASDAQ:VSAR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owningRead More...

  • Associated Press7 months ago

    Versartis: 2Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 27 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $1.78. A year ago, they were trading at $17.95. _____ ...

  • Versartis Stock and Its Consistent Rise in the Week Ended June 8
    Market Realist9 months ago

    Versartis Stock and Its Consistent Rise in the Week Ended June 8

    Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.

  • ACCESSWIRE9 months ago

    Wired News - CHMP Adopted Negative Opinion for Sarepta's EXONDYS in Europe to Treat Patients with Duchenne Muscular Dystrophy

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free research report on Sarepta Therapeutics, Inc. (NASDAQ: SRPT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SRPT as the Company's latest news hit the wire. On June 01, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion against approval for EXONDYS® (eteplirsen) for treatment of patients with Duchenne muscular dystrophy (DMD).

  • ACCESSWIRE9 months ago

    Free Technical Research on Versartis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).